Gonadotropins, often shortened to “GON” in medical settings, are protein-based hormones made from two linked chains of amino acids decorated with sugar molecules. In nature, your body produces them in the pituitary gland. As fertility medications (like the well-known brand Gonal-f), they are manufactured using genetically engineered hamster cells that produce a human-identical version of the hormone. Here’s a closer look at what goes into both the natural and pharmaceutical forms.
The Natural Hormone: Protein Plus Sugar
Gonadotropins belong to a class of molecules called glycoproteins, meaning they are part protein, part sugar. Each gonadotropin hormone is built from two separate protein chains called subunits: a common alpha subunit shared by all gonadotropins, and a unique beta subunit that determines which specific hormone it is. The beta subunit is what distinguishes follicle-stimulating hormone (FSH) from luteinizing hormone (LH) and from human chorionic gonadotropin (hCG, the “pregnancy hormone”).
Both subunits are decorated with branching sugar chains, a process called glycosylation. These sugar attachments aren’t just decoration. They influence how well the two protein chains lock together, how long the hormone survives in your bloodstream, and how effectively it activates its target cells. For example, removing certain sugar groups from the alpha subunit actually speeds up how quickly the two chains assemble. The precise pattern of sugars varies between the different gonadotropins: FSH and hCG each carry two sugar chains on their beta subunit, while LH typically carries one.
How Fertility Medications Are Made
When gonadotropins are prescribed as fertility drugs, they need to be virtually identical to the hormones your body makes naturally. Early versions were extracted from the urine of postmenopausal women, but modern formulations use recombinant DNA technology. The most common production method involves Chinese hamster ovary (CHO) cells, a workhorse of pharmaceutical manufacturing that has been used for decades to produce complex human proteins.
Scientists insert the human gene for FSH (or another gonadotropin) into these CHO cells, which then act as tiny biological factories. The cells grow in carefully controlled culture conditions and secrete the hormone into the surrounding liquid. That liquid is then put through extensive purification steps to isolate the hormone from everything else the cells produce. One commercially available recombinant FSH, produced by a CHO-based cell line, achieves a productivity rate of about 12.3 picograms per cell per day.
The advantage of this approach is consistency. Because the cells are clones grown under standardized conditions, every batch of medication is nearly identical in its protein structure and sugar patterns, something that was harder to guarantee with older urine-derived products.
What’s in the Final Medication
The active ingredient in a product like Gonal-f is follitropin alfa, the recombinant form of human FSH. But the vial contains more than just the hormone. Inactive ingredients include sucrose (which stabilizes the protein during freeze-drying), sodium phosphate buffers that keep the pH in the right range, and phosphoric acid or sodium hydroxide used for fine pH adjustments before the product is freeze-dried into powder form.
When you reconstitute the powder for injection, the diluent is bacteriostatic water containing 0.9% benzyl alcohol, which serves as a preservative. This matters for multi-dose vials that may be used over several days. The entire formulation is designed to keep the delicate protein structure intact from manufacturing through injection.
GnRH: The Hormone That Triggers Gonadotropin Release
Gonadotropins don’t appear on their own. Their release is triggered by another hormone called gonadotropin-releasing hormone, or GnRH. This is a much simpler molecule: a short chain of just 10 amino acids, compared to the large, sugar-coated two-chain structure of the gonadotropins themselves. In humans, the sequence is pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly. It’s produced in the hypothalamus and travels a short distance to the pituitary gland, where it signals the release of FSH and LH.
Synthetic versions of GnRH (called GnRH agonists) are also used in fertility treatment. These are designed to either stimulate or suppress the body’s own gonadotropin production, depending on how they’re administered. When given continuously, they initially trigger a surge of FSH and LH but then shut down production, giving doctors precise control over the timing of ovulation during assisted reproduction cycles.
Why the Sugar Chains Matter
One of the trickiest parts of manufacturing gonadotropins is getting the sugar chains right. If the alpha subunit fails to pair with a beta subunit during production, it ends up with abnormal sugar patterns. Overly complex, three-branched sugar structures can actually block the two subunits from joining at all. This is why manufacturers monitor glycosylation closely: the wrong sugar profile means a hormone that either doesn’t work properly or gets cleared from the body too quickly to be effective.
For patients, this translates into real differences in how well a medication works. Properly glycosylated gonadotropins bind more effectively to receptors on ovarian cells, produce more predictable responses, and maintain more stable blood levels after injection. It’s one of the reasons recombinant products, with their tightly controlled manufacturing, have largely replaced older formulations in clinical practice.